Director Vlad Coric Acquires Over $24.5M in Veradermics Stock Post-IPO
MANE is trading near its 52-week low of $32 (11% above the low).
Summary
Director Vlad Coric significantly increased his stake in Veradermics, Inc. through a substantial open market purchase and conversion of preferred stock, totaling over $24.5 million, following the company's IPO.
Key Events · Ownership and Investor Activity · MANE
-
Substantial Stock Acquisition
Director Vlad Coric acquired common stock totaling $24,594,457, representing a significant increase in his holdings.
-
Open Market Purchase at IPO Price
Included a direct open market purchase of 117,646 shares for $1,999,982 at $17.00 per share on February 5, 2026, matching the IPO price.
-
Preferred Stock Conversion Post-IPO
Converted Series A, B, and C Convertible Preferred Stock into 638,262 common shares, valued at $22,594,475, immediately prior to the IPO closing on February 5, 2026.
-
Strong Post-IPO Confidence
This significant insider accumulation follows the company's Initial Public Offering, demonstrating strong director confidence in Veradermics, Inc.'s future.
Analysis · MANE · Life Sciences
This Form 4 filing indicates a strong vote of confidence from Director Vlad Coric, who acquired a substantial amount of Veradermics, Inc. common stock. The transactions include an open market purchase of nearly $2 million at the IPO price and the conversion of over $22.5 million in preferred stock into common shares, occurring immediately after the company's Initial Public Offering. This significant accumulation of shares by a director, especially following an IPO, signals strong insider belief in the company's future prospects and aligns with other recent insider accumulation activity.
At the time of this filing, MANE was trading at $35.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $32.00 to $40.11. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.